|
TBC1D19 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.74638081773537E-13 |
| Normal-vs-Stage2 |
8.45759999812401E-08 |
| Normal-vs-Stage3 |
8.88178419700125E-15 |
| Normal-vs-Stage4 |
1.66022751102446E-12 |
| Stage1-vs-Stage2 |
8.192800E-01 |
| Stage1-vs-Stage3 |
6.479600E-02 |
| Stage1-vs-Stage4 |
6.764900E-03 |
| Stage2-vs-Stage3 |
1.381430E-01 |
| Stage2-vs-Stage4 |
3.874400E-02 |
| Stage3-vs-Stage4 |
4.165800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.952100E-04 |
| Normal-vs-Asian |
9.78260028539069E-10 |
| Caucasian-vs-AfricanAmerican |
6.489700E-02 |
| Caucasian-vs-Asian |
7.577800E-01 |
| AfricanAmerican-vs-Asian |
1.542040E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.28219657113959E-11 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
9.025000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.28039809258007E-12 |
| Normal-vs-Age(41-60Yrs) |
3.57602836231763E-13 |
| Normal-vs-Age(61-80Yrs) |
1.67421632113474E-12 |
| Normal-vs-Age(81-100Yrs) |
1.461880E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.810000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.668380E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.714200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.151200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.786000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.212800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.183900E-04 |
| Classical-VS-Follicular |
1.970980E-01 |
| Classical-VS-Other |
8.318600E-01 |
| Classical-VS-Normal |
1.6251444634463E-12 |
| Tall-VS-Follicular |
1.353050E-04 |
| Tall-VS-Other |
2.436400E-01 |
| Tall-VS-Normal |
1.62558855265615E-12 |
| Follicular-VS-Other |
8.182800E-01 |
| Follicular-VS-Normal |
1.07149999983847E-07 |
| Other-VS-Normal |
5.600500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.5527136788005E-14 |
| Normal-vs-N1 |
1.02695629777827E-12 |
| N0-vs-N1 |
6.638200E-02 |
|
|
